GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Tellgen Corp (SZSE:300642) » Definitions » ROE % Adjusted to Book Value

Tellgen (SZSE:300642) ROE % Adjusted to Book Value : 1.76% (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Tellgen ROE % Adjusted to Book Value?

Tellgen's ROE % for the quarter that ended in Dec. 2024 was 2.69%. Tellgen's PB Ratio for the quarter that ended in Dec. 2024 was 1.53. Tellgen's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 1.76%.


Tellgen ROE % Adjusted to Book Value Historical Data

The historical data trend for Tellgen's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tellgen ROE % Adjusted to Book Value Chart

Tellgen Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.41 3.25 3.77 3.14 1.49

Tellgen Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.46 -0.79 2.31 2.94 1.76

Competitive Comparison of Tellgen's ROE % Adjusted to Book Value

For the Medical Devices subindustry, Tellgen's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tellgen's ROE % Adjusted to Book Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tellgen's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Tellgen's ROE % Adjusted to Book Value falls into.


;
;

Tellgen ROE % Adjusted to Book Value Calculation

Tellgen's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=2.28% / 1.53
=1.49%

Tellgen's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=2.69% / 1.53
=1.76%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tellgen ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Tellgen's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Tellgen Business Description

Traded in Other Exchanges
N/A
Address
No. 412 Huiqing Road, Pudong New District, Shanghai, CHN, 201201
Tellgen Corp manufactures and distributes in vitro diagnostic devices for detection of tumor. Its products include tumor marker, human papillomavirus, real time PCR, DNA methylation, autoimmune antibody, infectious disease and others. The company has developed products in the fields of tumor detection, cervical cancer screening, DNA methylation detection, male infertility and prenatal and postnatal care. Its products include tumor marker series products, human papillomavirus series products, Y chromosome microdeletion detection products, real time PCR, autoimmune antibody, and others.
Executives
Zhou Ai Guo Directors, executives
Chen Si Han Securities Affairs Representative

Tellgen Headlines

No Headlines